Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Myeloma: Pathogenesis and Targeted Therapies
share announcement

Myeloma: Pathogenesis and Targeted Therapies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 462

Special Issue Editors

Dr. Fenghuang (Frank) Zhan

E-Mail Website
Guest Editor
Myeloma Center, Winthrop P. Rockefeller Cancer Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Interests: multiple myeloma; bone marrow microenvironment; molecular pathogenesis; CAR-T cell therapy; personalized medicine; drug resistance; immunotherapy targets; biomarkers; genetic alterations
Dr. Gang An

E-Mail
Guest Editor
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China
Interests: multiple myeloma; plasma cell disease; management of hematological malignancies
Dr. Cody Ashby

E-Mail Website
Guest Editor
Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Interests: multiple myeloma; cancer genomics; computational genomics; DNA sequencing; RNA sequencing; bioinformatics; algorithms

Special Issue Information

Dear Colleagues,

Multiple myeloma is driven by progressive genetic mutations and abnormal signaling pathways that support malignant plasma cell proliferation and survival. The bone marrow microenvironment plays a key role by providing survival signals and facilitating immune evasion through cytokines, growth factors, and cell–cell interactions. Understanding these mechanisms has led to targeted therapies that disrupt tumor-supportive pathways, enhance immune recognition, and overcome resistance. Combinatorial approaches have shown synergistic effects, marking a significant shift in treatment strategies. This Special Issue highlights recent advances in the pathogenesis and targeted treatment of multiple myeloma, aiming to showcase novel diagnostic tools, therapeutic strategies, and individualized treatment approaches in this evolving field.

We are pleased to invite you to contribute your latest research and insights on multiple myeloma, with a focus on disease pathogenesis and the evolving landscape of targeted therapies.

This Special Issue aims to provide a comprehensive overview of recent advances in understanding and treating this complex malignancy. We welcome original research articles and reviews covering a broad range of topics, including pathophysiology, bioinformatics techniques for targeted discovery, therapeutic strategies, and immunotherapeutic approaches. We invite you to be part of this collaborative effort.

Dr. Fenghuang (Frank) Zhan
Dr. Gang An
Dr. Cody Ashby
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma
  • drug resistance
  • car-t cell therapy
  • immunotherapy targets
  • biomarkers
  • genetic alterations
  • molecular pathogenesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 876 KB  
Article
Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma
by Chenxing Du, Jian Cui, Jingyu Xu, Wenqiang Yan, Lingna Li, Weiwei Sui, Shuhui Deng, Shuhua Yi, Yan Xu, Chengwen Li, Jiawei Zhao, Dehui Zou, Lugui Qiu and Gang An
Cancers 2025, 17(16), 2703; https://doi.org/10.3390/cancers17162703 - 20 Aug 2025
Viewed by 367
Abstract
Background: High-risk chromosomal abnormalities (HRCAs) detected by fluorescence in situ hybridization (FISH) have a well-established adverse prognostic impact in multiple myeloma (MM). It is increasingly recognized that the coexistence of two or more HRCAs identifies a particularly poor-risk subgroup, often referred to as [...] Read more.
Background: High-risk chromosomal abnormalities (HRCAs) detected by fluorescence in situ hybridization (FISH) have a well-established adverse prognostic impact in multiple myeloma (MM). It is increasingly recognized that the coexistence of two or more HRCAs identifies a particularly poor-risk subgroup, often referred to as double- or multiple-hit MM. However, there is currently no consensus on its definition. Methods: We retrospectively analyzed a multicenter cohort of 1122 newly diagnosed MM patients from 2008 to 2019. Double-hit MM was defined as the coexistence of at least two of the following four HRCAs: t(14;16), gain(1q), del(17p), and del(1p). Based on this definition, we constructed a novel prognostic model, the HBDH (Institute of Hematology & Blood Diseases Hospital) double-hit model, and assessed its prognostic value for progression-free survival (PFS) and overall survival (OS). Results: According to the HBDH model, double-hit patients showed significantly inferior outcomes compared to non-double-hit patients, with median PFS of 20.6 vs. 53.3 months (p < 0.001) and median OS of 40.2 vs. 84.2 months (p < 0.001). The addition of del(13q), t(4;14), or t(11;14) did not improve the prognostic performance of the model. Importantly, the HBDH model was independent of the International Staging System (ISS), elevated LDH, and advanced age. Conclusions: The HBDH double-hit model identifies a subset of ultra-high-risk MM patients carrying at least two major HRCAs, providing a simple and robust framework for prognostic stratification and a potential reference for future biologically driven treatment approaches. Full article
(This article belongs to the Special Issue Myeloma: Pathogenesis and Targeted Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop